JCI Insight (Apr 2022)

Characterization of disease-propagating stem cells responsible for myeloproliferative neoplasm–blast phase

  • Xiaoli Wang,
  • Raajit K. Rampal,
  • Cing Siang Hu,
  • Joseph Tripodi,
  • Noushin Farnoud,
  • Bruce Petersen,
  • Michael R. Rossi,
  • Minal Patel,
  • Erin McGovern,
  • Vesna Najfeld,
  • Camelia Iancu-Rubin,
  • Min Lu,
  • Andrew Davis,
  • Marina Kremyanskaya,
  • Rona Singer Weinberg,
  • John Mascarenhas,
  • Ronald Hoffman

Journal volume & issue
Vol. 7, no. 8

Abstract

Read online

Chronic myeloproliferative neoplasms (MPN) frequently evolve to a blast phase (BP) that is almost uniformly resistant to induction chemotherapy or hypomethylating agents. We explored the functional properties, genomic architecture, and cell of origin of MPN-BP initiating cells (IC) using a serial NSG mouse xenograft transplantation model. Transplantation of peripheral blood mononuclear cells (MNC) from 7 of 18 patients resulted in a high degree of leukemic cell chimerism and recreated clinical characteristics of human MPN-BP. The function of MPN-BP ICs was not dependent on the presence of JAK2V617F, a driver mutation associated with the initial underlying MPN. By contrast, multiple MPN-BP IC subclones coexisted within MPN-BP MNCs characterized by different myeloid malignancy gene mutations and cytogenetic abnormalities. MPN-BP ICs in 4 patients exhibited extensive proliferative and self-renewal capacity, as demonstrated by their ability to recapitulate human MPN-BP in serial recipients. These MPN-BP IC subclones underwent extensive continuous clonal competition within individual xenografts and across multiple generations, and their subclonal dynamics were consistent with functional evolution of MPN-BP IC. Finally, we show that MPN-BP ICs originate from not only phenotypically identified hematopoietic stem cells, but also lymphoid-myeloid progenitor cells, which were each characterized by differences in MPN-BP initiating activity and self-renewal capacity.

Keywords